Giles Francis J, List Alan F, Carroll Michael, Cortes Jorge E, Valickas Joyce, Chen Bee-Lian, Masson Eric, Jacques Christian, Laurent Dirk, Albitar Maher, Feldman Eric J, Roboz Gail J
The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA.
Leuk Res. 2007 Jul;31(7):891-7. doi: 10.1016/j.leukres.2006.12.001.
Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.
血管生成是伴有髓外化生的骨髓纤维化（MMM）病理生理学的一部分。PTK787/ZK 222584（PTK/ZK）是一种新型血管内皮生长因子受体抑制剂。29例MMM患者接受了PTK/ZK每日两次（BID）、剂量为500或750 mg的持续给药方案。15%的患者出现了短暂的、可能与PTK/ZK相关的轻度恶心、呕吐、头晕、疲劳、血小板减少或厌食。接受每日两次750 mg治疗的患者出现了消化不良、蛋白尿和/或粘膜炎等剂量限制性毒性。分别有1例（3%）和5例（17%）患者实现了完全缓解和临床改善。PTK/ZK在MMM患者中具有适度的活性。
